Therachon

Therachon is a global biotechnology company dedicated to developing drugs for rare genetic diseases that currently have no available treatments. The company's leading candidate drug, TA-46, is a novel protein therapy targeting achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research laboratories in Nice, France.